Altimmune Inc

Altimmune insider buying: Teri Lawver’s 48,800 options highlight management’s confidence in peptide‑based obesity/NASH candidates, offering investors a potential upside despite current low valuation.

Altimmune’s insider buying and $75 M offering boost confidence in pemvidutide’s Phase 2 obesity trial, signaling strong capital strategy and future growth potential.

Altimmune insider trades show executive confidence amid a negative earnings climate—find out how peptide‑based obesity and NASH therapies could lift the stock.

Altimmune insider buys 5,000 shares as FDA Breakthrough Therapy status boosts investor confidence, hinting at future growth.